Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) (CARE-FH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Behavioral: FH diagnosis program
- Behavioral: Implementation strategy package: Develop and implement tools for quality monitoring
- Behavioral: Implementation strategy package: Develop educational materials
- Behavioral: Implementation strategy package: Conduct educational outreach visits
- Behavioral: Implementation strategy package: Intervene with clinicians and patients to enhance
- Behavioral: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions
- Behavioral: Implementation strategy package: Audit and provide feedback
- Behavioral: Implementation strategy package: Stage implementation scale up
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Multiple Locations, Pennsylvania, United States, 00000
- Geisinger Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Primary care clinicians (pediatrician, community medicine, internal medicine) in the Geisinger Healthcare System
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Phase 1
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
|
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
|
|
Other: Phase 2
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
|
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
|
|
Other: Phase 3
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
|
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
|
|
Other: Phase 4
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
|
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
|
|
Other: Phase 5
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
|
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FH diagnosis rate (Aim 2)
Time Frame: Up to 45 months
|
FH diagnosis rate, is achieving both the scheduling of a clinic visit and evidence the clinician, at that visit, has completed evidence-based FH diagnostic evaluation, defined as completing one of: using the FH clinic note to document care, adding FH diagnosis on the problem list, using the FH smart-set (or ordered a genetic test for FH), making a referral to the lipid clinic, or starting a statin for an evidence-based indication
|
Up to 45 months
|
|
Acceptability (Aim 3)
Time Frame: Month 9, 12, 18, 24, 30, 36, 42
|
Clinician and patient satisfaction and self-efficacy with the FH diagnosis program
|
Month 9, 12, 18, 24, 30, 36, 42
|
|
Timeliness (Aim 4)
Time Frame: Up to 45 months
|
Time to FH screen, time to diagnostic evaluation, time to statin initiation
|
Up to 45 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Initiation medication use (Aim 2)
Time Frame: Up to 45 months
|
Initiation of lipid lowering medication by healthcare clinician
|
Up to 45 months
|
|
Lipid measurement (Aim 2)
Time Frame: Up to 45 months
|
Order of a lipid panel
|
Up to 45 months
|
|
Genetic testing (Aim 2)
Time Frame: Month 9, 12, 18, 24, 30, 36, 42
|
Order of a genetic test for FH
|
Month 9, 12, 18, 24, 30, 36, 42
|
|
Problem list diagnosis of FH (Aim 2)
Time Frame: Up to 45 months
|
Clinician adds diagnosis of FH to the patients problem list in the electronic health record
|
Up to 45 months
|
|
FH smartset (Aim 2)
Time Frame: Month 9, 12, 18, 24, 30, 36, 42
|
Clinician uses and completes all field of the FH smartset
|
Month 9, 12, 18, 24, 30, 36, 42
|
|
Best Practice Alert (Aim 2)
Time Frame: Up to 45 months
|
Clinician adheres to and acts on recommendation in the Best Practice Alert
|
Up to 45 months
|
|
FH Clinic Note (Aim 2)
Time Frame: Up to 45 months
|
Clinician completes the FH clinic note
|
Up to 45 months
|
|
Fidelity (Aim 3)
Time Frame: Up to 45 months
|
Documentation of adaptations to the FH diagnosis program
|
Up to 45 months
|
|
Cost (Aim 3)
Time Frame: Up to 45 months
|
Cost to implement the implementation strategy package
|
Up to 45 months
|
|
Function (Aim 4)
Time Frame: Up to 45 months
|
Return of genetic result to patient (if ordered and patient undergoes testing)
|
Up to 45 months
|
|
Function (Aim 4)
Time Frame: Up to 45 months
|
Reduction in lipid level from baseline to end of the study period
|
Up to 45 months
|
|
Function (Aim 4)
Time Frame: Up to 45 months
|
Patient side effects to medications
|
Up to 45 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Laney K Jones, PharmD, MPH, Geisinger Clinic
- Principal Investigator: Samuel S Gidding, MD, Geisinger Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Hyperlipidemias
- Dyslipidemias
- Lipid Metabolism Disorders
- Lipid Metabolism, Inborn Errors
- Hyperlipoproteinemias
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Hyperlipoproteinemia Type II
- Behavioral Disciplines and Activities
- Psychotherapy
Other Study ID Numbers
Other Study ID Numbers
- 2021-0927
- 1R61HL161775 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.